Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks
share announcement

Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 15117

Special Issue Editors

Dr. Gloria Alvarez-Llamas

E-Mail Website
Guest Editor
Department of Immunology, IIS-Fundacion Jimenez Diaz, UAM, RICORS2040, Avenida Reyes Católicos 2, 28040 Madrid, Spain
Interests: cardiovascular risk; atherosclerosis; thoracic aortic aneurysm; hypertension; chronic kidney disease; albuminuria; extracellular vesicles; proteomics; metabolomics
Special Issues, Collections and Topics in MDPI journals
Dr. Marta Martin-Lorenzo

E-Mail Website
Guest Editor
Department of Immunology, IIS-Fundacion Jimenez Diaz, UAM, Avenida Reyes Católicos 2, 28040, Madrid, Spain
Interests: proteomics; metabolomics; mass spectromerty imaging; cardiovascular disease; cardiovascular risk; atherosclerosis; thoracic aortic aneurysm; hypertension; acute kidney injury
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite enormous efforts for the prevention of cardiovascular diseases, they remain the leading cause of premature death worldwide. In most cases, atherosclerosis silent development hinders early or on-time diagnosis. The increased cardiovascular risk associated with other pathologies, such as chronic kidney disease, is well known and only partially explained by the existence of traditional risk factors such as hypertension and diabetes mellitus. Within this scenario, the multifactorial nature of cardiovascular risk calls for novel investigation and further knowledge on subjacent biological mechanisms.

Identifying the chemical phenotypes of health and/or disease using metabolomics is gaining attraction—particularly in the study of cardiovascular disease, where it has two aims: a) identification of novel molecular markers of cardiovascular risk and b) deciphering simultaneous changes taking place at the tissue level, which allows the elucidation of significant metabolic and protein pathways that are being modulated. This Special Issue is dedicated to all aspects of metabolite alterations during atherosclerosis development, chronic kidney disease, diabetic nephropathy and any other related pathology with increased cardiovascular risk. Identification of metabolic changes within protein networks using multiomics approaches is particularly encouraged, including methodological issues. Studies evidencing a potential role for metabolites in the incidence and progression of COVID-19 in subjects with cardiovascular comorbidities are also welcome.

Dr. Gloria Alvarez-Llamas
Dr. Marta Martin-Lorenzo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • metabolites
  • cardiovascular risk
  • atherosclerosis
  • chronic kidney disease
  • diabetic nephropathy
  • proteomics
  • COVID-19

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

10 pages, 620 KiB  
Review
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
by Jelena Vekic, Aleksandra Zeljkovic, Khalid Al Rasadi, Mustafa Cesur, José Silva-Nunes, Anca Pantea Stoian and Manfredi Rizzo
Metabolites 2022, 12(2), 108; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo12020108 - 24 Jan 2022
Cited by 23 | Viewed by 3209
Abstract
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes [...] Read more.
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk. Full article
(This article belongs to the Special Issue Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks)
►▼ Show Figures

Figure 1

17 pages, 1222 KiB  
Review
The “Common Soil Hypothesis” Revisited—Risk Factors for Type 2 Diabetes and Cardiovascular Disease
by Lilian Fernandes Silva, Jagadish Vangipurapu and Markku Laakso
Metabolites 2021, 11(10), 691; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11100691 - 09 Oct 2021
Cited by 12 | Viewed by 3649
Abstract
The prevalence and the incidence of type 2 diabetes (T2D), representing >90% of all cases of diabetes, are increasing rapidly worldwide. Identification of individuals at high risk of developing diabetes is of great importance, as early interventions might delay or even prevent full-blown [...] Read more.
The prevalence and the incidence of type 2 diabetes (T2D), representing >90% of all cases of diabetes, are increasing rapidly worldwide. Identification of individuals at high risk of developing diabetes is of great importance, as early interventions might delay or even prevent full-blown disease. T2D is a complex disease caused by multiple genetic variants in interaction with lifestyle and environmental factors. Cardiovascular disease (CVD) is the major cause of morbidity and mortality. Detailed understanding of molecular mechanisms underlying in CVD events is still largely missing. Several risk factors are shared between T2D and CVD, including obesity, insulin resistance, dyslipidemia, and hyperglycemia. CVD can precede the development of T2D, and T2D is a major risk factor for CVD, suggesting that both conditions have common genetic and environmental antecedents and that they share “common soil”. We analyzed the relationship between the risk factors for T2D and CVD based on genetics and population-based studies with emphasis on Mendelian randomization studies. Full article
(This article belongs to the Special Issue Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks)
►▼ Show Figures

Graphical abstract

20 pages, 2398 KiB  
Review
Browning of White Adipose Tissue as a Therapeutic Tool in the Fight against Atherosclerosis
by Christel L. Roth, Filippo Molica and Brenda R. Kwak
Metabolites 2021, 11(5), 319; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11050319 - 14 May 2021
Cited by 17 | Viewed by 4283
Abstract
Despite continuous medical advances, atherosclerosis remains the prime cause of mortality worldwide. Emerging findings on brown and beige adipocytes highlighted that these fat cells share the specific ability of non-shivering thermogenesis due to the expression of uncoupling protein 1. Brown fat is established [...] Read more.
Despite continuous medical advances, atherosclerosis remains the prime cause of mortality worldwide. Emerging findings on brown and beige adipocytes highlighted that these fat cells share the specific ability of non-shivering thermogenesis due to the expression of uncoupling protein 1. Brown fat is established during embryogenesis, and beige cells emerge from white adipose tissue exposed to specific stimuli like cold exposure into a process called browning. The consecutive energy expenditure of both thermogenic adipose tissues has shown therapeutic potential in metabolic disorders like obesity and diabetes. The latest data suggest promising effects on atherosclerosis development as well. Upon cold exposure, mice and humans have a physiological increase in brown adipose tissue activation and browning of white adipocytes is promoted. The use of drugs like β3-adrenergic agonists in murine models induces similar effects. With respect to atheroprotection, thermogenic adipose tissue activation has beneficial outcomes in mice by decreasing plasma triglycerides, total cholesterol and low-density lipoproteins, by increasing high-density lipoproteins, and by inducing secretion of atheroprotective adipokines. Atheroprotective effects involve an unaffected hepatic clearance. Latest clinical data tend to find thinner atherosclerotic lesions in patients with higher brown adipose tissue activity. Strategies for preserving healthy arteries are a major concern for public health. Full article
(This article belongs to the Special Issue Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks)
►▼ Show Figures

Figure 1

Other

Jump to: Review

12 pages, 522 KiB  
Brief Report
Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial
by Nerea Becerra-Tomás, Miguel Ruiz-Canela, Pablo Hernández-Alonso, Mònica Bulló, Jun Li, Marta Guasch-Ferré, Estefanía Toledo, Clary B. Clish, Ramon Estruch, Emilio Ros, Montserrat Fitó, Chih-Hao Lee, Kerry Pierce, Fernando Arós, Lluís Serra-Majem, Liming Liang, Cristina Razquin, Enrique Gómez-Gracia, Miguel A. Martínez-González, Frank B. Hu, Dolores Corella and Jordi Salas-Salvadóadd Show full author list remove Hide full author list
Metabolites 2021, 11(5), 306; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11050306 - 11 May 2021
Cited by 4 | Viewed by 3033
Abstract
The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and [...] Read more.
The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case–control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR for 1 SD increase: 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies. Full article
(This article belongs to the Special Issue Cardiovascular Risk Biomarkers: Deciphering the Metabolism and Interaction Networks)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop